Literature DB >> 6508974

Plasma disposition of vitamin K1 in relation to anticoagulant poisoning.

B K Park, A K Scott, A C Wilson, B P Haynes, A M Breckenridge.   

Abstract

The disposition of vitamin K1, after intravenous (10 mg) and oral doses (10 mg and 50 mg) was studied in six healthy male subjects. After intravenous administration, the plasma concentration-time profile was adequately fitted with an average terminal half-life of 1.7 h. After oral administration (10 mg and 50 mg) the availability of vitamin K showed marked inter-individual variation (10-63%). With the higher dose intra-individual variation was also observed. Experiments in brodifacoum-anticoagulated rabbits demonstrate that the duration of action of a pharmacological dose (10 mg/kg) is short (9 h) and that high plasma concentrations (ca 1 microgram/ml) of the vitamin are required to drive clotting factor synthesis during maximum coumarin anticoagulation. Taken collectively, these data indicate that the short duration of action of vitamin K, frequently observed in cases of coumarin poisoning, is a consequence of requirements for high vitamin K concentrations and rapid clearance of the vitamin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6508974      PMCID: PMC1463546          DOI: 10.1111/j.1365-2125.1984.tb02526.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  28 in total

1.  Warfarin and the inhibition of vitamin K activity by an oxide metabolite.

Authors:  R G Bell; J T Matschiner
Journal:  Nature       Date:  1972-05-05       Impact factor: 49.962

2.  Vitamin K1 absorption by everted intestinal sacs of the rat.

Authors:  D Hollander
Journal:  Am J Physiol       Date:  1973-08

3.  Clearance from plasma and excretion in urine, faeces and bile of an intravenous dose of tritiated vitamin K 1 in man.

Authors:  M J Shearer; C N Mallinson; G R Webster; P Barkhan
Journal:  Br J Haematol       Date:  1972-05       Impact factor: 6.998

4.  Characterization of vitamin K from human liver.

Authors:  T J Duello; J T Matschiner
Journal:  J Nutr       Date:  1972-03       Impact factor: 4.798

5.  Bioassay of vitamin K by intracardial injection in deficient adult male rats.

Authors:  J T Matschiner; W V Taggart
Journal:  J Nutr       Date:  1968-01       Impact factor: 4.798

6.  Absorption, distribution, storage, and metabolites of vitamins K and related quinones.

Authors:  O Wiss; H Gloor
Journal:  Vitam Horm       Date:  1966       Impact factor: 3.421

7.  Cyclic interconversion of vitamin K1 and vitamin K1 2,3-epoxide in man.

Authors:  H Bechtold; D Trenk; T Meinertz; M Rowland; E Jähnchen
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

8.  Changes in phylloquinone epoxidase activity related to prothrombin synthesis and microsomal clotting activity in the rat.

Authors:  A K Willingham; J T Matschiner
Journal:  Biochem J       Date:  1974-06       Impact factor: 3.857

9.  Mechanism of action of warfarin. Warfarin and metabolism of vitamin K 1 .

Authors:  R G Bell; J A Sadowski; J T Matschiner
Journal:  Biochemistry       Date:  1972-05-09       Impact factor: 3.162

Review 10.  Studies on the absorption and metabolism of phylloquinone (vitamin K1) in man.

Authors:  M J Shearer; A McBurney; P Barkhan
Journal:  Vitam Horm       Date:  1974       Impact factor: 3.421

View more
  16 in total

1.  The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin.

Authors:  I A Choonara; R G Malia; B P Haynes; C R Hay; S Cholerton; A M Breckenridge; F E Preston; B K Park
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

2.  Oral cholestyramine increases elimination of warfarin after overdose.

Authors:  S Renowden; D Westmoreland; J P White; P A Routledge
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-24

3.  Enantiomers of warfarin and vitamin K1 metabolism.

Authors:  I A Choonara; B P Haynes; S Cholerton; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

4.  Abnormal vitamin K metabolism in the presence of normal clotting factor activity in factory workers exposed to 4-hydroxycoumarins.

Authors:  B K Park; I A Choonara; B P Haynes; A M Breckenridge; R G Malia; F E Preston
Journal:  Br J Clin Pharmacol       Date:  1986-03       Impact factor: 4.335

5.  Proceedings of the British Pharmacological Society. University of Southampton, 17th-19th July 1985. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1985-09       Impact factor: 8.739

6.  Vitamin K prodrugs: 2. water-soluble prodrugs of menahydroquinone-4 for systemic site-specific delivery.

Authors:  J Takata; Y Karube; M Hanada; K Matsunaga; Y Matsushima; T Sendo; R Oishi
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

7.  A hetero-dimer model for concerted action of vitamin K carboxylase and vitamin K reductase in vitamin K cycle.

Authors:  Sangwook Wu; Shubin Liu; Charles H Davis; Darrel W Stafford; John D Kulman; Lee G Pedersen
Journal:  J Theor Biol       Date:  2011-03-29       Impact factor: 2.691

8.  Warfarin poisoning and vitamin K antagonism in rat and human liver. Design of a system in vitro that mimics the situation in vivo.

Authors:  R Wallin; L F Martin
Journal:  Biochem J       Date:  1987-01-15       Impact factor: 3.857

Review 9.  Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship.

Authors:  N H Holford
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

10.  Vitamin K prodrugs: 1. Synthesis of amino acid esters of menahydroquinone-4 and enzymatic reconversion to an active form.

Authors:  J Takata; Y Karube; M Hanada; K Matsunaga; Y Matsushima; T Sendo; T Aoyama
Journal:  Pharm Res       Date:  1995-01       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.